NCT03131908 2025-12-15
Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
Clinical Trials
5 trialsNCT04439149 2025-11-21
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439188 2025-11-19
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02215096 2020-10-22
Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer
GlaxoSmithKline
Phase 1 Completed
NCT01458067 2018-07-24
A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency
GlaxoSmithKline
Phase 1 Completed